NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia

dc.contributor.authorPereira, Daniela A.
dc.contributor.authorSandrim, Valeria C. [UNESP]
dc.contributor.authorPalei, Ana C.
dc.contributor.authorAmaral, Lorena M.
dc.contributor.authorBelo, Vanessa A.
dc.contributor.authorLacchini, Riccardo
dc.contributor.authorCavalli, Ricardo C.
dc.contributor.authorTanus-Santos, Jose E.
dc.contributor.authorLuizon, Marcelo R.
dc.contributor.institutionUniversidade Federal de Minas Gerais (UFMG)
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversity of Mississippi Medical Center
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.date.accessioned2021-06-25T11:03:48Z
dc.date.available2021-06-25T11:03:48Z
dc.date.issued2021-06-01
dc.description.abstractAim: We examined the relationships between visfatin/NAMPT and nitrite concentrations (a marker of nitric oxide [NO] formation) or sFlt-1 levels in 205 patients with preeclampsia (PE) responsive or nonresponsive to antihypertensive therapy, and whether NAMPT SNPs rs1319501 and rs3801266 affect nitrite concentrations in PE and 206 healthy pregnant women. Patients & methods: Circulating visfatin/NAMPT and sFlt-1 levels were measured by ELISA, and nitrite concentrations by using an ozone-based chemiluminescence assay. Results: In nonresponsive PE patients, visfatin/NAMPT levels were inversely related to nitrite concentrations and positively related to sFlt-1 levels. NAMPT SNP rs1319501 affected nitrite concentrations in nonresponsive PE patients and was tightly linked with NAMPT functional SNPs in Europeans. Conclusion: NAMPT SNP rs1319501 and visfatin/NAMPT affect NO formation, sFlt-1 levels and antihypertensive therapy response in PE.en
dc.description.affiliationGraduate Program in Genetics Institute of Biological Sciences Federal University of Minas Gerais
dc.description.affiliationDepartment of Biophysics and Pharmacology Institute of Biosciences Universidade Estadual Paulista (UNESP)
dc.description.affiliationDepartment of Surgery University of Mississippi Medical Center
dc.description.affiliationDepartment of Pharmacology and Toxicology University of Mississippi Medical Center
dc.description.affiliationDepartment of Psychiatric Nursing and Human Sciences Ribeirao Preto College of Nursing University of Sao Paulo
dc.description.affiliationDepartment of Gynecology and Obstetrics Ribeirao Preto Medical School University of Sao Paulo
dc.description.affiliationDepartment of Pharmacology Ribeirao Preto Medical School University of Sao Paulo
dc.description.affiliationDepartment of Genetics Ecology and Evolution Institute of Biological Sciences Federal University of Minas Gerais
dc.description.affiliationUnespDepartment of Biophysics and Pharmacology Institute of Biosciences Universidade Estadual Paulista (UNESP)
dc.format.extent451-464
dc.identifierhttp://dx.doi.org/10.2217/pgs-2021-0006
dc.identifier.citationPharmacogenomics, v. 22, n. 8, p. 451-464, 2021.
dc.identifier.doi10.2217/pgs-2021-0006
dc.identifier.issn1744-8042
dc.identifier.issn1462-2416
dc.identifier.scopus2-s2.0-85107488118
dc.identifier.urihttp://hdl.handle.net/11449/207954
dc.language.isoeng
dc.relation.ispartofPharmacogenomics
dc.sourceScopus
dc.subjectantihypertensive agents
dc.subjectgenetic polymorphisms
dc.subjectnicotinamide phosphoribosyltransferase
dc.subjectnitric oxide
dc.subjectpharmacogenetics
dc.subjectpreeclampsia
dc.subjectsFlt-1
dc.subjectvisfatin/NAMPT
dc.titleNAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsiaen
dc.typeArtigo

Arquivos